This meeting is supported by:

OVERVIEW

Registration is now closed

The SMR is pleased to announce the return of the popular two day Target to Patient 2026 (T2P26) conference which will be held at the Wellcome Genome Campus, Hinxton, nr Cambridge, UK on April 20th and 21st, 2026. This is the third occurrence of this biennual meeting which will focus on ground-breaking advances during the following sessions following the drug discovery journey from Target to Patient:

1. Machine Learning and Target identification
2. Rewiring biology through induced proximity
3. Impact of advances in analytical sciences
4. Complex in vitro models
5. Improving clinical trial outcomes

We are delighted to have the following plenary speakers:

• Professor Dame Carol Robinson DBE FRS FMedSci FRSC (Dr Lee's Professor of Chemistry, Oxford; Director of the Kavli Institute for Nanoscience Discovery, Oxford: co-founder and Chief Scientific Consultant of OMass)
• Dr Cathy Vickers (Head of Innovation, NC3Rs)
• Dr Malcom Skingle CBE FMedSci (formerly Director Academic Liaison, GSK)

Participants from industry, academia and government interested in challenging the existing approaches to target selection and translation are encouraged to attend, and set the agenda for the next era of drug discovery.

Attendees will experience presentations from our esteemed panel of speakers, participate in live Q&A and panel discussion sessions, take advantage of networking opportunities, poster sessions, vendor exhibitions and on-demand materials.